Morgan Stanley’s Mersana Therapeutics MRSN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Shares
Change %
Capital Flow Portfolio Weight Portfolio Position
2025
Q2
$106K Buy
14,304
+2,019
+16% +$14.9K ﹤0.01% 6111
2025
Q1
$106K Sell
12,285
-35,849
-74% -$308K ﹤0.01% 5986
2024
Q4
$1.72M Sell
48,134
-6,435
-12% -$230K ﹤0.01% 4807
2024
Q3
$2.58M Sell
54,569
-36,335
-40% -$1.72M ﹤0.01% 4469
2024
Q2
$4.57M Sell
90,904
-26,803
-23% -$1.35M ﹤0.01% 3956
2024
Q1
$13.2M Sell
117,707
-213,057
-64% -$23.9M ﹤0.01% 3110
2023
Q4
$19.2M Buy
330,764
+291,323
+739% +$16.9M ﹤0.01% 3380
2023
Q3
$1.25M Buy
39,441
+8,861
+29% +$281K ﹤0.01% 4666
2023
Q2
$2.52M Sell
30,580
-45,365
-60% -$3.73M ﹤0.01% 4270
2023
Q1
$7.8M Buy
75,945
+5,626
+8% +$578K ﹤0.01% 3380
2022
Q4
$10.3M Buy
70,319
+6,536
+10% +$958K ﹤0.01% 3055
2022
Q3
$10.8M Buy
63,783
+835
+1% +$141K ﹤0.01% 2883
2022
Q2
$7.27M Sell
62,948
-23,907
-28% -$2.76M ﹤0.01% 3405
2022
Q1
$8.66M Buy
86,855
+37,711
+77% +$3.76M ﹤0.01% 3075
2021
Q4
$7.64M Buy
49,144
+22,428
+84% +$3.49M ﹤0.01% 3247
2021
Q3
$6.3M Buy
26,716
+21,669
+429% +$5.11M ﹤0.01% 3433
2021
Q2
$1.71M Buy
5,047
+4,518
+854% +$1.53M ﹤0.01% 4748
2021
Q1
$213K Sell
529
-1,301
-71% -$524K ﹤0.01% 5631
2020
Q4
$1.22M Buy
1,830
+1,259
+220% +$837K ﹤0.01% 4546
2020
Q3
$265K Sell
571
-280
-33% -$130K ﹤0.01% 4963
2020
Q2
$498K Buy
851
+656
+336% +$384K ﹤0.01% 4597
2020
Q1
$28K Sell
195
-2,847
-94% -$409K ﹤0.01% 5695
2019
Q4
$436K Buy
3,042
+2,340
+333% +$335K ﹤0.01% 5000
2019
Q3
$27K Sell
702
-5,613
-89% -$216K ﹤0.01% 5927
2019
Q2
$639K Buy
6,315
+6,042
+2,213% +$611K ﹤0.01% 4474
2019
Q1
$36K Sell
273
-503
-65% -$66.3K ﹤0.01% 5810
2018
Q4
$79K Sell
776
-48
-6% -$4.89K ﹤0.01% 5629
2018
Q3
$206K Sell
824
-243
-23% -$60.8K ﹤0.01% 5445
2018
Q2
$476K Buy
1,067
+85
+9% +$37.9K ﹤0.01% 5141
2018
Q1
$387K Buy
982
+405
+70% +$160K ﹤0.01% 5149
2017
Q4
$237K Sell
577
-50
-8% -$20.5K ﹤0.01% 5351
2017
Q3
$271K Buy
+627
New +$271K ﹤0.01% 5208